GRAIL (STU:NL0) Inventories, Raw Materials & Components: €15.5 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NL0 GRAIL Inc STU:NL0
11 GF Score
Price €93.06
! 2 Warning Signs
View Full Analysis

What is GRAIL Inventories, Raw Materials & Components?

GRAIL STU:NL0 +1.54% 11 Inventories, Raw Materials & Components is €15.5 Mil as of Jun. 2026. GuruFocus rates STU:NL0 with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

GRAIL's inventories, raw materials & components for the quarter that ended in Jun. 2026 was €15.5 Mil.

GRAIL's quarterly raw materials increased from Dec. 2025 (€13.6 Mil) to Mar. 2026 (€14.9 Mil) and increased from Mar. 2026 (€14.9 Mil) to Jun. 2026 (€15.5 Mil).

GRAIL's annual raw materials declined from Dec. 2023 (€19.6 Mil) to Dec. 2024 (€18.0 Mil) and declined from Dec. 2024 (€18.0 Mil) to Dec. 2025 (€13.6 Mil).

GRAIL Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for GRAIL's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GRAIL Inventories, Raw Materials & Components Chart

GRAIL Annual Data
Trend Dec18 Dec19 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial - 18.51 19.64 17.99 13.64

GRAIL Quarterly Data
Sep19 Sep20 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.82 15.65 13.64 14.92 15.54
STU:NL0
11GF Score
GRAIL Inc STU:NL0
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GRAIL Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €15.5 Mil mean?
GRAIL (STU:NL0) has a Inventories, Raw Materials & Components of €15.5 Mil as of Jun. 2026. Raw materials are the components a company uses for its main products. View historical data on GRAIL and its competitors.
Is GRAIL's Inventories, Raw Materials & Components too high?
GRAIL's current Inventories, Raw Materials & Components is €15.5 Mil. Overall, GRAIL has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does GRAIL's Inventories, Raw Materials & Components compare to VCYT and ADPT?
GRAIL's Inventories, Raw Materials & Components of €15.5 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Medical Diagnostics & Research company?
A good Inventories, Raw Materials & Components depends on the Medical Diagnostics & Research industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on GRAIL and its competitors. GRAIL's current Inventories, Raw Materials & Components is €15.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRAIL stock overvalued right now?
GRAIL (STU:NL0) has a current Inventories, Raw Materials & Components of €15.5 Mil. The current Inventories, Raw Materials & Components is €15.5 Mil. GRAIL's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For GRAIL (STU:NL0), the current Inventories, Raw Materials & Components is €15.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GRAIL Business Description

Other Exchanges GRAL:USANL0:Germany
Address 1525 O’Brien Drive, Menlo Park, CA, USA, 94025
GRAIL Inc. is a US healthcare company focused on early cancer detection through blood-based testing. Its flagship product, Galleri, is a multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to identify signals associated with more than fifty cancer types, including many that lack recommended screening. GRAIL also offers targeted methylation-based research-use products and laboratory services. The company serves healthcare providers, health systems, employers, and life insurance partners, primarily in the United States, with additional availability in the United Kingdom through partnerships such as the NHS-Galleri trial. Revenue comes from sales of the Galleri test and related services, alongside research collaborations and pharmaceutical partnerships. GRAIL operates a single reportable segment and continues to pursue regulatory approvals and clinical validation to expand adoption of its MCED platform.
11GF Score

Get the complete analysis for STU:NL0

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€93.06
Price